[Muscle-Specific Receptor Tyrosine Kinase Antibody Positive Myasthenia Gravis]

Area of Science:

• Neurology
• Immunology

Background:

• Myasthenia gravis (MG) is an autoimmune disorder affecting neuromuscular junctions.
• Muscle-specific kinase (MuSK) antibody-positive MG constitutes a distinct subtype, representing approximately 3.0% of MG cases in Japan.
• MuSK-MG shares some clinical features with acetylcholine receptor antibody-positive MG but exhibits unique epidemiological and clinical characteristics.

Purpose of the Study:

• To delineate the specific clinical and epidemiological features of MuSK antibody-positive myasthenia gravis.
• To highlight the diagnostic challenges and therapeutic strategies for MuSK-MG.

Main Methods:

• Retrospective analysis of patient data.
• Serological testing for MuSK antibodies.
• Clinical assessment of disease presentation and severity.

Main Results:

• MuSK-MG is characterized by young-onset disease and a female predominance.
• Ocular involvement is infrequent (5.9%), while dysphagia is more severe compared to acetylcholine receptor antibody-positive MG.
• Clinical and electrophysiological tests are insufficient for differentiating MuSK-MG from other subtypes, necessitating antibody measurement.

Conclusions:

• Diagnosis of MuSK-MG relies on specific antibody detection.
• Treatment approaches for MuSK-MG differ from other MG subtypes, excluding thymectomy and complement inhibitors.
• Current treatments include acetylcholinesterase inhibitors, steroids, immunosuppressants, plasma exchange, IVIg, and emerging neonatal Fc receptor inhibitors.